| In Vitro |
ZIKV-IN-1 (compound 38) (0-80 µM) shows anti-ZIKV activity in a dose-dependent manner in A549 cells[1]. ZIKV-IN-1 (5, 10, 25 µM; 48 h) decreases the expression of ZIKV E and cleaved caspase 3 protein[1]. ZIKV-IN-1 (1.25, 2.5, 5, 10, 20 µM; 0-250 s) shows strong affinity to ZIKV RdRp domain (Kd=1.87 µM) in A549 cells[1]. Cell Viability Assay[1] Cell Line: A549 cells Concentration: 0-50 µM Incubation Time: Result: Showed anti-ZIKV activity with an EC50 of 2.8 µM, EC90 of 6.8 µM, and CC50 of >50 µM. Western Blot Analysis[1] Cell Line: A549, Vero cells Concentration: 5, 10, 25 µM Incubation Time: 48 h Result: Decreased the expression of ZIKV E and cleaved caspase 3 protein. Cell Cytotoxicity Assay[1] Cell Line: Vero, SNB19, Huh7, A549 cells Concentration: 0-80 µM Incubation Time: Result: Showed low cytotoxicity with CC50s of 46.8, 49.4, 43.8, 54.1 µM for ZG01 strain of Vero, SNB19, Huh7, A549 cells, and CC50s of 470.5, 485.2, 512.8, 160.8 µM for MR766 strain of Vero, SNB19, Huh7, A549 cells, respectively.
|
